NO2785538T3 - - Google Patents

Info

Publication number
NO2785538T3
NO2785538T3 NO12794266A NO12794266A NO2785538T3 NO 2785538 T3 NO2785538 T3 NO 2785538T3 NO 12794266 A NO12794266 A NO 12794266A NO 12794266 A NO12794266 A NO 12794266A NO 2785538 T3 NO2785538 T3 NO 2785538T3
Authority
NO
Norway
Application number
NO12794266A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2785538T3 publication Critical patent/NO2785538T3/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278Knock-in vertebrates, e.g. humanised vertebrates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5406IL-4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082Supracellular entities, e.g. tissue, organisms
    • G01N33/5088Supracellular entities, e.g. tissue, organisms of vertebrates
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00Modified animals
    • A01K2207/15Humanized animals
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/07Animals genetically altered by homologous recombination
    • A01K2217/072Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/20Animal model comprising regulated expression system
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/01Animal expressing industrially exogenous proteins
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/035Animal model for multifactorial diseases
    • A01K2267/0368Animal model for inflammation
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/0393Animal model comprising a reporter system for screening tests

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Environmental Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO12794266A 2014-05-07 2012-11-22 NO2785538T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461989757P 2014-05-07 2014-05-07

Publications (1)

Publication Number Publication Date
NO2785538T3 true NO2785538T3 (pl) 2018-08-04

Family

ID=53284509

Family Applications (1)

Application Number Title Priority Date Filing Date
NO12794266A NO2785538T3 (pl) 2014-05-07 2012-11-22

Country Status (26)

Country Link
US (7) US9565841B2 (pl)
EP (3) EP3281521B1 (pl)
JP (4) JP6640740B2 (pl)
KR (2) KR102473565B1 (pl)
CN (2) CN110269047B (pl)
AU (3) AU2015255977B2 (pl)
BR (1) BR112016025745A2 (pl)
CA (2) CA3207834A1 (pl)
CY (2) CY1119773T1 (pl)
DK (2) DK3281521T3 (pl)
ES (2) ES2656529T3 (pl)
HR (2) HRP20211455T1 (pl)
HU (2) HUE038028T2 (pl)
IL (3) IL248358B2 (pl)
LT (2) LT3027015T (pl)
MX (1) MX370672B (pl)
NO (1) NO2785538T3 (pl)
NZ (2) NZ725615A (pl)
PH (1) PH12016502058A1 (pl)
PL (2) PL3281521T3 (pl)
PT (2) PT3027015T (pl)
RS (2) RS57073B1 (pl)
RU (1) RU2703139C2 (pl)
SG (2) SG11201608570YA (pl)
SI (2) SI3027015T1 (pl)
WO (1) WO2015171861A1 (pl)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2785538T3 (pl) 2014-05-07 2018-08-04
WO2015196051A1 (en) 2014-06-19 2015-12-23 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized programmed cell death 1 gene
EP3212819B1 (en) * 2014-09-17 2023-03-29 Oerlikon Surface Solutions AG, Pfäffikon Method for producing a double-layer coated cutting tool with improved wear resistance
CN113016720B (zh) 2014-11-24 2023-02-21 瑞泽恩制药公司 表达人源化cd3复合物的非人类动物
LT3850946T (lt) 2014-12-05 2024-01-10 Regeneron Pharmaceuticals, Inc. Gyvūnai, išskyrus žmogų, turintys humanizuotą ląstelės diferenciacijos klasterio 47 geną
RU2711729C2 (ru) 2014-12-09 2020-01-21 Регенерон Фармасьютикалз, Инк. Не относящиеся к человеку животные, имеющие гуманизированный ген кластера дифференцировки 274
WO2017087780A1 (en) 2015-11-20 2017-05-26 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized lymphocyte-activation gene 3
WO2017136712A1 (en) 2016-02-04 2017-08-10 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered angptl8 gene
KR102493894B1 (ko) 2016-02-29 2023-01-31 리제너론 파마슈티칼스 인코포레이티드 인간화 tmprss 유전자를 갖는 설치류
TWI784988B (zh) * 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
EP3610041A1 (en) 2017-04-13 2020-02-19 Regeneron Pharmaceuticals, Inc. Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1
CA3066918A1 (en) 2017-06-12 2018-12-20 Bluefin Biomedicine, Inc. Anti-il1rap antibodies and antibody drug conjugates
BR112020003609A2 (pt) 2017-09-29 2020-09-01 Regeneron Pharmaceuticals, Inc. sistema e método para formar uma emulsão
KR102709884B1 (ko) 2017-11-30 2024-09-26 리제너론 파마슈티칼스 인코포레이티드 인간화된 trkb 유전자좌를 포함하는 비인간 동물
JP7328243B2 (ja) 2018-03-26 2023-08-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 治療薬を試験するためのヒト化げっ歯類
IL277890B2 (en) 2018-04-11 2024-03-01 Regeneron Pharma Methods for quantification of IL-33
JP7048051B2 (ja) 2018-07-11 2022-04-05 正徳 染井 痒みを軽減するアトピー性皮膚炎治療剤
US11589562B2 (en) * 2018-07-16 2023-02-28 Regeneran Pharmaceuticals, Inc. Mouse model of DITRA disease and uses thereof
CN111057721B (zh) * 2018-10-12 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化IL-4和/或IL-4Rα改造动物模型的制备方法及应用
CN114107385A (zh) * 2019-01-17 2022-03-01 百奥赛图(北京)医药科技股份有限公司 人源化转基因动物
SG11202108454RA (en) 2019-04-04 2021-09-29 Regeneron Pharma Non-human animals comprising a humanized coagulation factor 12 locus
JP2022534867A (ja) 2019-06-04 2022-08-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ベータスリップ変異を有するヒト化ttr遺伝子座を含む非ヒト動物と使用方法
CN113939595A (zh) 2019-06-07 2022-01-14 瑞泽恩制药公司 包括人源化白蛋白基因座的非人动物
WO2021018198A1 (en) * 2019-07-29 2021-02-04 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric il33
CN112430621B (zh) * 2019-08-09 2022-09-27 百奥赛图(北京)医药科技股份有限公司 Il2ra基因人源化的非人动物的构建方法及应用
EP4057807A4 (en) * 2019-11-11 2023-12-27 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC GENES
WO2021129766A1 (zh) * 2019-12-25 2021-07-01 江苏集萃药康生物科技股份有限公司 一种il-15人源化小鼠模型及其用途
EP4096396A1 (en) * 2020-01-28 2022-12-07 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized pnpla3 locus and methods of use
CN111149767B (zh) * 2020-02-24 2021-07-20 中南大学湘雅二医院 一种人源化皮肤型红斑狼疮小鼠模型的构建方法和应用
CN113527485A (zh) * 2020-04-17 2021-10-22 上海麦济生物技术有限公司 抗人白细胞介素-4受体α抗体及其制备方法和应用
CN111808882B (zh) * 2020-09-01 2020-12-29 北京百奥赛图基因生物技术有限公司 Il7r基因人源化改造的动物模型的构建方法及其应用
CN111793646B (zh) * 2020-09-08 2021-01-15 北京百奥赛图基因生物技术有限公司 Il1r1基因人源化改造的非人动物的构建方法及其应用
CN111926039B (zh) * 2020-09-23 2021-03-16 百奥赛图(北京)医药科技股份有限公司 Il-13基因人源化的非人动物的构建方法和应用
US20220192165A1 (en) * 2020-12-21 2022-06-23 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized tslp gene, a humanized tslp receptor gene, and/or a humanized il7ra gene
WO2022247936A1 (en) * 2021-05-28 2022-12-01 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric cd36
WO2024067796A1 (zh) * 2022-09-28 2024-04-04 百奥赛图(北京)医药科技股份有限公司 一种il5和/或il5ra基因人源化修饰的非人动物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU643427B2 (en) * 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
ES2463476T3 (es) 2004-10-19 2014-05-28 Regeneron Pharmaceuticals, Inc. Método para generar un ratón homocigótico para una modificación genética
JP2007252370A (ja) * 2006-02-22 2007-10-04 Institute Of Physical & Chemical Research Il−4初期発現系トランスジェニック非ヒト動物およびその利用
US20110016543A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genomic editing of genes involved in inflammation
SG176118A1 (en) * 2009-06-29 2011-12-29 Qingfeng Chen Methods of producing humanized non-human mammals
CA2767377A1 (en) * 2009-07-24 2011-01-27 Sigma-Aldrich Co. Llc Method for genome editing
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
DK3056082T3 (en) 2009-10-06 2018-12-17 Regeneron Pharma RE-MODIFIED MICE AND INPUT
ES2948210T3 (es) 2011-02-15 2023-09-06 Regeneron Pharma Ratones humanizados con M-CSF y uso de los mismos
PL3262932T3 (pl) 2011-10-28 2019-10-31 Regeneron Pharma Genetycznie zmodyfikowany główny układ zgodności tkankowej myszy
PT2663575E (pt) * 2011-10-28 2014-12-05 Regeneron Pharma Il-6 e receptor de il-6 humanizados
KR101926442B1 (ko) 2011-10-28 2018-12-12 리제너론 파아마슈티컬스, 인크. 키메라 주요 조직적합성 복합체 (mhc) ii 분자들을 발현하는 유전자 변형된 마우스
US8962913B2 (en) * 2012-06-18 2015-02-24 Regeneron Pharmaceuticals, Inc. Humanized IL-7 rodents
CN110624107A (zh) * 2012-08-21 2019-12-31 赛诺菲生物技术公司 通过施用il-4r拮抗剂治疗或预防哮喘的方法
KR20240045263A (ko) 2012-09-07 2024-04-05 예일 유니버시티 유전적으로 변형된 비-인간 동물 및 이것들의 사용 방법
EP4389764A3 (en) 2012-11-05 2024-08-14 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals and methods of use thereof
KR102313047B1 (ko) 2013-02-20 2021-10-19 리제너론 파아마슈티컬스, 인크. 사람화된 t-세포 보조-수용체를 발현하는 마우스
CN105164154B (zh) 2013-02-22 2019-06-07 瑞泽恩制药公司 表达人源化主要组织相容性复合物的小鼠
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
US9193977B2 (en) 2013-09-23 2015-11-24 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized signal-regulatory protein gene
CA2926090C (en) 2013-10-15 2022-07-05 Regeneron Pharmaceuticals, Inc. Humanized il-15 animals
ES2703549T3 (es) 2013-11-19 2019-03-11 Regeneron Pharma Animales no humanos que tienen un gen de un ligando inductor de la proliferación humanizado
JP6505689B2 (ja) 2013-11-19 2019-04-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. ヒト化b細胞活性化因子遺伝子を有する非ヒト動物
ES2794942T3 (es) 2014-04-08 2020-11-19 Regeneron Pharma Animales no humanos que tienen receptores Fc-gamma humanizados
NZ726602A (en) 2014-05-05 2024-05-31 Regeneron Pharmaceuticals Inc Humanized c5 and c3 animals
NO2785538T3 (pl) 2014-05-07 2018-08-04

Also Published As

Publication number Publication date
HRP20211455T1 (hr) 2022-01-07
EP3027015A1 (en) 2016-06-08
EP3281521A1 (en) 2018-02-14
KR20160150637A (ko) 2016-12-30
AU2015255977A1 (en) 2016-11-17
RS57073B1 (sr) 2018-06-29
US9743647B2 (en) 2017-08-29
HRP20180242T1 (hr) 2018-03-09
US9565841B2 (en) 2017-02-14
JP7145250B2 (ja) 2022-09-30
AU2024204694A1 (en) 2024-09-05
RU2016143376A3 (pl) 2018-11-22
WO2015171861A1 (en) 2015-11-12
SG11201608570YA (en) 2016-11-29
CN110269047B (zh) 2021-11-02
EP3906781A1 (en) 2021-11-10
IL297105B2 (en) 2024-01-01
US20170311580A1 (en) 2017-11-02
RS62345B1 (sr) 2021-10-29
CN106470545A (zh) 2017-03-01
US11963521B2 (en) 2024-04-23
CN106470545B (zh) 2019-08-20
SG10201912354PA (en) 2020-02-27
CA2947307C (en) 2023-09-26
SI3281521T1 (sl) 2021-11-30
IL297105B1 (en) 2023-09-01
DK3027015T3 (en) 2018-01-22
SI3027015T1 (en) 2018-02-28
CA3207834A1 (en) 2015-11-12
IL248358A0 (en) 2016-11-30
BR112016025745A2 (pt) 2018-01-16
US10588298B2 (en) 2020-03-17
ES2887852T3 (es) 2021-12-28
IL297105A (en) 2022-12-01
RU2019131253A (ru) 2019-12-06
EP3281521B1 (en) 2021-06-30
JP2021087434A (ja) 2021-06-10
RU2703139C2 (ru) 2019-10-15
NZ725615A (en) 2024-05-31
NZ763861A (en) 2024-05-31
ES2656529T3 (es) 2018-02-27
LT3027015T (lt) 2018-01-25
US20150320022A1 (en) 2015-11-12
AU2015255977B2 (en) 2021-09-02
CA2947307A1 (en) 2015-11-12
HUE038028T2 (hu) 2018-09-28
RU2016143376A (ru) 2018-06-09
CY1119773T1 (el) 2018-06-27
JP6640740B2 (ja) 2020-02-05
PL3027015T3 (pl) 2018-04-30
PL3281521T3 (pl) 2022-01-03
US20180000056A1 (en) 2018-01-04
MX2016014563A (es) 2017-02-23
HUE055860T2 (hu) 2021-12-28
US20230027494A1 (en) 2023-01-26
DK3281521T3 (da) 2021-09-20
IL304841A (en) 2023-09-01
EP3027015B1 (en) 2017-11-08
US20150320021A1 (en) 2015-11-12
JP2022171841A (ja) 2022-11-11
LT3281521T (lt) 2021-09-27
PT3281521T (pt) 2021-09-16
JP2020058379A (ja) 2020-04-16
US10477842B2 (en) 2019-11-19
US11109578B2 (en) 2021-09-07
IL248358B (en) 2022-11-01
KR102473565B1 (ko) 2022-12-02
KR102517112B1 (ko) 2023-04-03
MX370672B (es) 2019-12-19
PH12016502058A1 (en) 2017-01-09
JP2017514501A (ja) 2017-06-08
PT3027015T (pt) 2018-02-09
KR20220165814A (ko) 2022-12-15
US20200022344A1 (en) 2020-01-23
JP6838131B2 (ja) 2021-03-03
US20210368753A1 (en) 2021-12-02
AU2021218060B2 (en) 2024-04-11
CN110269047A (zh) 2019-09-24
AU2021218060A1 (en) 2021-09-09
IL248358B2 (en) 2023-03-01
CY1124605T1 (el) 2022-07-22

Similar Documents

Publication Publication Date Title
BR112014017635A2 (pl)
BR112014017614A2 (pl)
BR112014017625A2 (pl)
BR112014017659A2 (pl)
BR112014017646A2 (pl)
BR112014017638A2 (pl)
BR112014018648A2 (pl)
BR112014017607A2 (pl)
BR112014024237A2 (pl)
BR112014018115A2 (pl)
BR112014017634A2 (pl)
BR112014017609A2 (pl)
BR112014017644A2 (pl)
BR112014017588A2 (pl)
BR112014017647A2 (pl)
BR112014017618A2 (pl)
BR112014013184A8 (pl)
BR112014017630A2 (pl)
BR112014017652A2 (pl)
BR112014025138A2 (pl)
BR112014017621A2 (pl)
BR112014017622A2 (pl)
BR112014017627A2 (pl)
BR112014017623A2 (pl)
BR112014023519A2 (pl)